Literature DB >> 23834844

Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice.

Aviva Katzav1, Maria T Arango, Shaye Kivity, Susumu Tanaka, Gili Givaty, Nancy Agmon-Levin, Makoto Honda, Juan-Manuel Anaya, Joab Chapman, Yehuda Shoenfeld.   

Abstract

Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness and cataplexy (a sudden weakening of posture muscle tone usually triggered by emotion) caused by the loss of orexin neurons in the hypothalamus. Autoimmune mechanisms are implicated in narcolepsy by increased frequency of specific HLA alleles and the presence of specific autoantibody (anti-Tribbles homolog 2 (TRIB2) antibodies) in the sera of patients with narcolepsy. Presently, we passively transferred narcolepsy to naïve mice by injecting intra-cerebra-ventricularly (ICV) pooled IgG positive for anti-TRIB2 antibodies. Narcolepsy-IgG-injected mice had a loss of the NeuN (neuronal marker), synaptophysin (synaptic marker) and orexin-positive neurons in the lateral hypothalamus area in narcolepsy compared to control-IgG-injected mice and these changes were associated with narcolepsy-like immobility attacks at four weeks post injection and with hyperactivity and long term memory deficits in the staircase and novel object recognition tests. Similar behavioral and cognitive deficits are observed in narcoleptic patients. This is the first report of passive transfer of experimental narcolepsy to naïve mice induced by autoantibodies and supports the autoimmune pathogenesis in narcolepsy.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-Tribbles homolog 2 (TRIB2) antibodies; Behavioral deficits; Narcolepsy; Orexin; Passive transfer

Mesh:

Substances:

Year:  2013        PMID: 23834844     DOI: 10.1016/j.jaut.2013.06.010

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  21 in total

1.  The challenge of treating orphan disease.

Authors:  Carlos Dias; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  Narcolepsy Associated with Pandemrix Vaccine.

Authors:  Tomi Sarkanen; Anniina Alakuijala; Ilkka Julkunen; Markku Partinen
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-01       Impact factor: 5.081

3.  Neuroimmunology: Disease mechanisms in narcolepsy remain elusive.

Authors:  Ilkka Julkunen; Markku Partinen
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

Review 4.  Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.

Authors:  Lucie Barateau; Roland Liblau; Christelle Peyron; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

Review 5.  Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction.

Authors:  Yahel Segal; Yehuda Shoenfeld
Journal:  Cell Mol Immunol       Date:  2018-03-05       Impact factor: 11.530

Review 6.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

7.  Unique topics and issues in rheumatology and clinical immunology.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

8.  Euflammation Attenuates Central and Peripheral Inflammation and Cognitive Consequences of an Immune Challenge after Tumor Development.

Authors:  Savannah R Bever; Xiaoyu Liu; Ning Quan; Leah M Pyter
Journal:  Neuroimmunomodulation       Date:  2017-09-13       Impact factor: 2.492

Review 9.  Autoimmunity in narcolepsy.

Authors:  Melodie Bonvalet; Hanna M Ollila; Aditya Ambati; Emmanuel Mignot
Journal:  Curr Opin Pulm Med       Date:  2017-11       Impact factor: 3.155

10.  Injection of celiac disease patient sera or immunoglobulins to mice reproduces a condition mimicking early developing celiac disease.

Authors:  Suvi Kalliokoski; Sergio Caja; Rafael Frias; Kaija Laurila; Outi Koskinen; Onni Niemelä; Markku Mäki; Katri Kaukinen; Ilma R Korponay-Szabó; Katri Lindfors
Journal:  J Mol Med (Berl)       Date:  2014-09-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.